ArticleJournal of inflammation (London, England)2025
Activation of the aryl hydrocarbon receptor relieves acute pancreatitis via the RBX1/HSF1 pathway.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAcute pancreatitis (AP) represents one of the most prevalent acute gastrointestinal disorders. Research has indicated a significant correlation between aryl hydrocarbon receptor (AhR) signaling and pancreatic injury associated with AP. Nevertheless, the specific role of AhR signaling in tight junction injury induced by AP remains to be fully understood.
methodsAn experimental model of severe AP was established through repeated cerulein injections in conjunction with a single LPS injection. We evaluated pancreatic injury by quantifying serum amylase activity, LDH levels, pancreatic MPO levels, histopathological changes, tight junction protein expression, and the infiltration and polarization of macrophages. The regulatory interactions between AhR and HSF1 were analyzed through experimental validation and predictions derived from the BioGRID and Ubibrowser databases.
resultsAhR exhibited low expression and a negative correlation with the M1 polarization of pancreatic resident macrophages (PRM). In primary acinar cells treated with cerulein, AhR enhanced the activation of HSF1 signaling and mitigated the impairment of tight junction integrity. Conditioned medium from primary acinar cells overexpressing AhR resulted in the M2 polarization of PRM. RBX1 was identified as a potential mediator of the interaction between AhR and HSF1. RBX1 was found to facilitate HSF1 ubiquitination through its binding to HSF1, thereby promoting its degradation. Finally, AhR overexpression reduced cerulein/LPS-induced damage to pancreatic tight junction integrity in AP mice, while triptolide inhibited the therapeutic effects.
conclusionAhR facilitates the ubiquitination modification of HSF1 through its interaction with RBX1. This results in the suppression of HSF1 expression and activation, thereby mitigating cerulein/LPS-induced damage to pancreatic tight junctions in AP mice CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.